We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
Moderna's shares increased by over 10% due to progress in H5N1 vaccine development following a human fatality in the U.S.
Johnson & Johnson's new lung cancer regimen, Rybrevant and Lazcluze, shows a notable survival advantage over AstraZeneca's Tagrisso, sparking hope for better patient outcomes.
Neumora Therapeutics' shares drop as navacaprant fails in a critical depression drug trial amid hopes for a successful outcome.
The 2025 weight-loss drug market faces challenges with competition and supply constraints, impacting key players like Novo Nordisk and Amgen, as indicated by recent data and expert insights.
Discover how innovations in veterinary healthcare, including brain surgery and nanotechnology, are driving industry growth and changing consumer priorities.
Learn about FDA's approval of an injectable version of Opdivo, offering a more convenient cancer treatment option.
Pharmaceutical companies are fiercely competing in the obesity drug market, with Eli Lilly and Novo Nordisk among the major players. Innovations and collaborations are key in this dynamic and lucrative sector.
Novo Nordisk's shares plummet after CagriSema weight-loss drug trials fall short, impacting the company's market position significantly.
Merck's new HIV drug combination meets key clinical trial endpoints, offering hope for more effective HIV treatments.
Novo Holdings finalizes a $16.5 billion takeover of Catalent, marking a significant milestone in the pharmaceutical industry and strengthening its healthcare sector presence.
Teva and Sanofi shares surged as their joint clinical trial for ulcerative colitis and Crohn's disease treatment showed promising results, achieving key endpoints.
Pfizer forecasts 2025 sales between $61B-$64B, meeting Wall Street expectations, amid strategic moves like cost cuts and leadership in R&D.
131
